Mean ISS7 at baseline—DUPIXENT: 16.25 (SD, 3.90); placebo: 15.74 (SD, 4.11).2
vs 33% reductiona in ISS7 at Week 24
(DUPIXENT: -8.50 vs placebo: -6.13; P=0.0270, primary endpoint)1,2
- 37% vs 28% reductiona in ISS7 at Week 12 (DUPIXENT: -6.98 vs placebo: -5.34, secondary endpoint; not significant)2
- Mean ISS7 at baseline: DUPIXENT (n=73): 15.18 (SD, 3.59); placebo (n=75): 14.96 (SD, 3.94)1,2
Definitive conclusions cannot be made for Week 12 as the analysis was not multiplicity controlled.
aLSM change from baseline.
IMPROVEMENT IN ISS7 WAS OBSERVED AS EARLY AS WEEK 3 IN A POST HOC POOLED ANALYSIS
Mean ISS7 at baseline—DUPIXENT: 15.7 (SD, 3.77); placebo: 15.33 (SD, 4.02).2
Definitive conclusions cannot be made as this was a post hoc analysis which was not multiplicity controlled.
CONSISTENT ITCH IMPROVEMENT REGARDLESS
OF ANGIOEDEMA IN A POST HOC POOLED ANALYSIS
CUPID-C
Definitive conclusions cannot be made as this was a post hoc subgroup analysis which was not multiplicity controlled.
IN POST HOC POOLED ANALYSES OF CUPID-A AND CUPID-C, IMPROVEMENT IN ISS7:
At Week 24 was consistent regardless of patients’ baseline IgE1,2
At Week 24 was generally consistent regardless of baseline BMI2,b
Definitive conclusions cannot be made as these were post hoc analyses which were not multiplicity controlled.
bAcross BMI stratifications: BMI (kg/m2) <25, ≥25 to <30, and ≥30.
BMI, body mass index; HSS7, hives severity score over 7 days; ISS7, itch severity score over 7 days; LSM, least squares mean; SD, standard deviation.
Explore more data
Itch severity score (ISS) is a patient-reported assessment rated on a scale of 0 (none), 1 (mild itch), 2 (moderate itch), and 3 (intense itch). ISS7 is the sum of the preceding 7 days’ itch scores, for a total ISS7 range of 0 to 21.2
SEE WHICH PATIENTS WITH CSU MAY BE APPROPRIATE FOR DUPIXENT